Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reporte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Case Rep Dermatol
Egile Nagusiak: Bilgiç Temel, Aslı, Bassorgun, Cumhur Ibrahim, Akman-Karakaş, Ayşe, Alpsoy, Erkan, Uzun, Soner
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: S. Karger AG 2017
Gaiak:
Single Case
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346946/
https://ncbi.nlm.nih.gov/pubmed/28413387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452828
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak